+

WO2005075484A3 - Chemokine ccr5 receptor modulators - Google Patents

Chemokine ccr5 receptor modulators Download PDF

Info

Publication number
WO2005075484A3
WO2005075484A3 PCT/EP2005/000976 EP2005000976W WO2005075484A3 WO 2005075484 A3 WO2005075484 A3 WO 2005075484A3 EP 2005000976 W EP2005000976 W EP 2005000976W WO 2005075484 A3 WO2005075484 A3 WO 2005075484A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
receptor modulators
diaza
oxa
spiro
Prior art date
Application number
PCT/EP2005/000976
Other languages
French (fr)
Other versions
WO2005075484A2 (en
Inventor
Stephen Deems Gabriel
David Mark Rotstein
Original Assignee
Hoffmann La Roche
Stephen Deems Gabriel
David Mark Rotstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Stephen Deems Gabriel, David Mark Rotstein filed Critical Hoffmann La Roche
Priority to CA002554671A priority Critical patent/CA2554671A1/en
Priority to BRPI0507586-6A priority patent/BRPI0507586A/en
Priority to EP05707116A priority patent/EP1716156A2/en
Priority to JP2006552503A priority patent/JP2007522160A/en
Priority to AU2005211499A priority patent/AU2005211499A1/en
Publication of WO2005075484A2 publication Critical patent/WO2005075484A2/en
Publication of WO2005075484A3 publication Critical patent/WO2005075484A3/en
Priority to IL176720A priority patent/IL176720A0/en
Priority to NO20063495A priority patent/NO20063495L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to piperidine derivatives of formulae (I) with substituents as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. More particularly, the present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one and 1-oxa-3,9-diaza-spiro[5.5]undecan-2-one compounds and related derivatives, to compositions containing and to uses of such derivatives. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), diseases of the immune system and inflammatory diseases.
PCT/EP2005/000976 2004-02-10 2005-02-01 Chemokine ccr5 receptor modulators WO2005075484A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002554671A CA2554671A1 (en) 2004-02-10 2005-02-01 Chemokine ccr5 receptor modulators
BRPI0507586-6A BRPI0507586A (en) 2004-02-10 2005-02-01 ccr5 chemokine receptor modulators
EP05707116A EP1716156A2 (en) 2004-02-10 2005-02-01 Chemokine ccr5 receptor modulators
JP2006552503A JP2007522160A (en) 2004-02-10 2005-02-01 Chemokine CCR5 receptor modulator
AU2005211499A AU2005211499A1 (en) 2004-02-10 2005-02-01 Chemokine CCR5 receptor modulators
IL176720A IL176720A0 (en) 2004-02-10 2006-07-05 Chemokine ccr5 receptor modulators
NO20063495A NO20063495L (en) 2004-02-10 2006-07-31 Chemokine CCR5 receptor modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54340804P 2004-02-10 2004-02-10
US60/543,408 2004-02-10

Publications (2)

Publication Number Publication Date
WO2005075484A2 WO2005075484A2 (en) 2005-08-18
WO2005075484A3 true WO2005075484A3 (en) 2005-10-20

Family

ID=34837578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/000976 WO2005075484A2 (en) 2004-02-10 2005-02-01 Chemokine ccr5 receptor modulators

Country Status (15)

Country Link
US (2) US7332500B2 (en)
EP (1) EP1716156A2 (en)
JP (1) JP2007522160A (en)
KR (1) KR100863854B1 (en)
CN (1) CN100497346C (en)
AR (1) AR047536A1 (en)
AU (1) AU2005211499A1 (en)
BR (1) BRPI0507586A (en)
CA (1) CA2554671A1 (en)
CO (1) CO5700742A2 (en)
IL (1) IL176720A0 (en)
NO (1) NO20063495L (en)
RU (1) RU2006132465A (en)
TW (1) TW200529857A (en)
WO (1) WO2005075484A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6374762B1 (en) * 1997-10-27 2002-04-23 Correct Craft, Inc. Water sport towing apparatus
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
JP2008510728A (en) * 2004-08-19 2008-04-10 バーテックス ファーマシューティカルズ インコーポレイテッド Muscarinic receptor modulators
JP2008521825A (en) * 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド Muscarinic receptor modulators
DE602006014531D1 (en) * 2005-03-03 2010-07-08 Janssen Pharmaceutica Nv SUBSTITUTED OXADIAZASPIRO-Ä5.5Ü-UNDECANON DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS
BRPI0608847A2 (en) 2005-03-08 2010-02-02 Janssen Pharmaceutica Nv substituted diaza-spiro [4,4] nonnon derivatives and their use as neurokinin antagonists
KR20080056220A (en) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 Phenyl-acetamide NNT inhibitors
JP2009521483A (en) * 2005-12-22 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Muscarinic receptor modulators
JP2009527568A (en) * 2006-02-22 2009-07-30 バーテックス ファーマシューティカルズ インコーポレイテッド Modulator of muscarinic receptor
AU2007221220A1 (en) * 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Spiro condensed piperidnes as modulators of muscarinic receptors
AU2007269863A1 (en) * 2006-06-29 2008-01-10 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2007284548A1 (en) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
DE602007013573D1 (en) 2006-08-16 2011-05-12 Hoffmann La Roche NON-NUCLEOSIDIC REVERSE TRANSCRIPTASE INHIBITORS
CA2660974A1 (en) 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2007332654B2 (en) 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
WO2008090944A1 (en) * 2007-01-25 2008-07-31 Takeda Pharmaceutical Company Limited Spiro-ring compound
EP2142555A1 (en) * 2007-03-29 2010-01-13 F. Hoffmann-Roche AG Heterocyclic antiviral compounds
US7977358B2 (en) * 2007-07-26 2011-07-12 Hoffmann-La Roche Inc. Pyrazol derivatives
WO2009037168A1 (en) * 2007-09-19 2009-03-26 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
MX2010003373A (en) * 2007-10-03 2010-04-30 Vertex Pharma Modulators of muscarinic receptors.
CA2723080A1 (en) * 2008-05-09 2009-11-12 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
EP2440251A4 (en) 2009-06-09 2013-01-16 Defyrus Inc Administration of interferon for prophylaxis against or treatment of pathogenic infection
EP2721025B1 (en) * 2011-06-16 2015-11-25 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
SG11201402405QA (en) 2011-11-18 2014-09-26 Heptares Therapeutics Ltd Muscarinic m1 receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
US10927128B2 (en) * 2015-11-16 2021-02-23 Esteve Pharmaceuticals. S.A. Oxadiazaspiro compounds for the treatment of drug abuse and addiction
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
US10501483B2 (en) 2017-10-24 2019-12-10 Allergan, Inc. Enamines and diastereo-selective reduction of enamines
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048828A1 (en) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
EP4240355A4 (en) * 2020-11-03 2024-10-09 Cassava Sciences, Inc. INHIBITION OF AN IMMUNE RESPONSE BY ONE OR MORE TLR2, RAGE, CCR5, CXCR4 AND CD4

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399192A (en) * 1964-04-22 1968-08-27 Science Union & Cie 1-oxa-2-oxo 3, 8-diaza spiro (4, 5) decanes
EP0414422A2 (en) * 1989-08-10 1991-02-27 Richter Gedeon Vegyeszeti Gyar R.T. 2-Oxo-1-oxa-8-azaspiro [4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof
WO2000066558A1 (en) * 1999-05-04 2000-11-09 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
WO2001064213A1 (en) * 2000-03-02 2001-09-07 Smithkline Beecham Corporation Compounds and methods
WO2002092604A1 (en) * 2001-05-14 2002-11-21 F. Hoffmann-La Roche Ag 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ320963A (en) 1995-09-29 1999-08-30 Lilly Co Eli Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
DK1175402T3 (en) 1999-05-04 2005-11-21 Schering Corp Piperidine derivatives useful as CCR5 antagonists
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6689765B2 (en) * 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
TWI224597B (en) 1999-12-03 2004-12-01 Ono Pharmaceutical Co Triazaspiro[5.5]undecane derivatives and a medicine containing the derivatives as an active ingredient
WO2001057044A1 (en) 2000-02-01 2001-08-09 Daiichi Pharmaceutical Co., Ltd. Pyridoxazine derivatives
NZ571695A (en) * 2001-12-28 2010-02-26 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399192A (en) * 1964-04-22 1968-08-27 Science Union & Cie 1-oxa-2-oxo 3, 8-diaza spiro (4, 5) decanes
EP0414422A2 (en) * 1989-08-10 1991-02-27 Richter Gedeon Vegyeszeti Gyar R.T. 2-Oxo-1-oxa-8-azaspiro [4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof
WO2000066558A1 (en) * 1999-05-04 2000-11-09 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
WO2001064213A1 (en) * 2000-03-02 2001-09-07 Smithkline Beecham Corporation Compounds and methods
WO2002092604A1 (en) * 2001-05-14 2002-11-21 F. Hoffmann-La Roche Ag 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor

Also Published As

Publication number Publication date
US7332500B2 (en) 2008-02-19
JP2007522160A (en) 2007-08-09
KR100863854B1 (en) 2008-10-15
CN100497346C (en) 2009-06-10
CN1918171A (en) 2007-02-21
US20080139544A1 (en) 2008-06-12
NO20063495L (en) 2006-11-01
RU2006132465A (en) 2008-03-20
BRPI0507586A (en) 2007-07-03
KR20060108770A (en) 2006-10-18
EP1716156A2 (en) 2006-11-02
AU2005211499A1 (en) 2005-08-18
WO2005075484A2 (en) 2005-08-18
IL176720A0 (en) 2006-10-31
TW200529857A (en) 2005-09-16
CO5700742A2 (en) 2006-11-30
US7538122B2 (en) 2009-05-26
CA2554671A1 (en) 2005-08-18
AR047536A1 (en) 2006-01-25
US20050176703A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
WO2005075484A3 (en) Chemokine ccr5 receptor modulators
NO20061978L (en) Imidazopyridine-substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation
NO20054085L (en) Substituted hexahydropyrazino [1,2-a] pyrimidine-4,7-dione derivatives, methods of preparation and use thereof as medicaments
WO2004054974A3 (en) Piperidine derivatives as ccr5 antagonists
AP1789A (en) Tropane derivatives useful in therapy.
BRPI0411825B8 (en) 5-element heterocycle-based p38 kinase inhibitors, their preparation processes and their uses, as well as pharmaceutical composition
WO2004054581A3 (en) Cyclohexyl compounds as ccr5 antagonists
ATE458735T1 (en) PYRIDINO[1,2-A PYRIMIDINE-4-ONE COMPOUNDS AS ANTI-CANCER AGENT
WO2006005609A3 (en) Substituted oxindol derivatives and medicaments containing the same
DE60222931D1 (en) PYRAZOLOPYRIMIDINONE DERIVATIVES WITH PDE7-HEMMENDER EFFECT
AU2003296993A1 (en) Cyclopropyl compounds as ccr5 antagonists
WO2006031715A3 (en) Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)
NO20091489L (en) Thiazole pyrazolopyridines as CRF1 receptor antagonists
MX2007011695A (en) Substituted oxindole derivatives, medicaments containing the latter and use thereof.
NO20051503L (en) Pyrazolopyridines and processes for the preparation and use of the same.
WO2007067875A3 (en) Pyridinyl sulfonamide modulators of chemokine receptors
AU2003228674A1 (en) Muscarinic antagonists
NO20072831L (en) Imidazo [1,2-A] Pyridine Compounds, Compositions, Uses and Methods Related thereto
MX2007011698A (en) Substituted oxindole derivatives, medicaments containing the latter and use thereof.
AU2003300911A1 (en) Heterocyclic compounds as ccr5 antagonists
WO2006072458A3 (en) Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
NO20080033L (en) Quinoline derivatives as NK3 antagonists
BRPI0413013A (en) compound, its salts, solvates, and pharmaceutically functional derivatives, pharmaceutical composition, use of a compound, and methods for the treatment or prophylaxis of conditions or disorders, and diseases
NO20055766L (en) Positive modulators of nicotine acetylcholine receptors
ATE433450T1 (en) SUBSTITUTED 1,4,8-TRIAZASPIRO 4.5 DECAN-2-ON COMPOUNDS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005707116

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 176720

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 548363

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005211499

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2554671

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 06074877

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 12006501504

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2890/CHENP/2006

Country of ref document: IN

Ref document number: PA/a/2006/008948

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020067016037

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005211499

Country of ref document: AU

Date of ref document: 20050201

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006552503

Country of ref document: JP

Ref document number: 200580004518.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005211499

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006132465

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 1020067016037

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2005707116

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0507586

Country of ref document: BR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载